If these animal models reflect human disease, focused strategies targeting TPL-2 would benefit from identifying a prognostic biomarker and treating patients with type-1/17-associated fibrosis, rather than patients with type-2-associated fibrosis. Here, MAP3K8 is linked to fibrosis.